expanding treatment options for aml to patients with mds
Published 1 year ago • 89 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
2:38
managing the progression of mds to aml
-
1:36
innovations in mds and aml treatment
-
2:13
optimizing therapy for patients with high-risk mds
-
2:02
oral azacitidine maintenance in aml with mds-related changes: insights from quazar aml-001
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:13
treatment approaches for patients with r/r aml and the importance of preventing relapse
-
2:07
updates in treatment options for patients with aml
-
2:09
advances in the management of fit adults with aml
-
4:48
managing and treating mds
-
25:18
addressing the major challenges to car-t therapy in aml
-
4:28
understanding myelodysplastic syndromes (mds)
-
4:28
current and emerging treatment options for mds
-
4:14
treatment landscape for elderly acute myeloid leukemia (aml) patients
-
0:55
the role of rna modifications in mds and aml
-
1:08
approved and emerging treatment options for transplant-ineligible patients with high-risk mds
-
2:11
the current role of immuno-oncology in aml and future outlooks
-
3:04
expanding mds therapy options
-
1:02
bispecific agents: the future of aml and mds treatment?
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
2:04
eha and asco 2023 highlights: promising treatments in aml, mds, and all
-
3:34
anti-cd47 antibodies & azacitidine for aml and mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os